These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 15273334)

  • 41. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Flusser G; Zuriel L; Kollender Y; Lerman H; Lievshitz G; Ron I; Mishani E
    J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.
    Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Beuschlein F; Wängler B; Uebleis C; Schmidt GP; Spitzweg C; Bartenstein P; Hacker M
    Radiology; 2014 Feb; 270(2):517-25. PubMed ID: 24056402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
    J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
    Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
    JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.
    Schöder H; Yeung HW; Gonen M; Kraus D; Larson SM
    Radiology; 2004 Apr; 231(1):65-72. PubMed ID: 14990824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
    Kim BS; Kim IJ; Kim SJ; Pak K; Kim K
    Onkologie; 2011; 34(6):298-303. PubMed ID: 21625182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The value of positron emission tomography in the diagnosis of recurrent rectal cancer].
    Lehner B; Schlag P; Strauss L; Dimitrakopoulou A; Herfarth C
    Zentralbl Chir; 1990; 115(13):813-7. PubMed ID: 2238957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
    Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
    Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma.
    Graafland NM; Leijte JA; Valdés Olmos RA; Hoefnagel CA; Teertstra HJ; Horenblas S
    Eur Urol; 2009 Aug; 56(2):339-45. PubMed ID: 19477581
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
    Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
    J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer.
    Kitajima K; Murakami K; Yamasaki E; Hagiwara S; Fukasawa I; Inaba N; Kaji Y; Sugimura K
    Ann Nucl Med; 2008 Feb; 22(2):103-9. PubMed ID: 18311534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma.
    Etchebehere EC; Romanato JS; Santos AO; Buzaid AC; Camargo EE
    Nucl Med Commun; 2010 Nov; 31(11):925-30. PubMed ID: 20856153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma.
    Even-Sapir E; Lerman H; Figer A; Rabau M; Livshitz G; Inbar M; Gutman M
    J Nucl Med; 2002 May; 43(5):603-9. PubMed ID: 11994521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Visual and quantitative comparison of (18)F-fluorodeoxyglucose PET/CT findings in the detection of pelvic tumor recurrence in colorectal cancer.
    Hwang HS; Han YM; Choi YJ; Koh SH; Park HC
    Ann Nucl Med; 2016 Jun; 30(5):355-61. PubMed ID: 26931104
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical value of F-FDG PET/CT in assessing suspicious relapse after rectal cancer resection.
    Sun L; Guan YS; Pan WM; Luo ZM; Wei JH; Zhao L; Wu H
    World J Gastrointest Oncol; 2009 Oct; 1(1):55-61. PubMed ID: 21160775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.